Phase II clinical study of the safety and efficacy of sintilimab in combination with axitinib and stereotactic radiotherapy in the treatment of local-regional recurrent renal cell cancer.

被引：0
|
作者：
Liu, Ruiqi
Liu, Yang
Zhang, Zhiling
Gao, Jianming
Zhang, Xinyue
Pan, Qiwen
Li, Yilin
Cai, Lingling
Guo, Shengjie
Han, Hui
Zhou, Fangjian
Dong, Pei
He, Liru
机构：
[1] Sun Yat Sen Univ, Dept Radiat Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Urol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16511
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I-II study to evaluate safety and efficacy of capecitabine (Xeloda) and exisulind (Aptosyn) combination therapy in patients with metastatic breast cancer.
    Pusztai, L
    Nealy, KM
    Pallansch, P
    Rivera, E
    Valero, V
    Cristofanilli, M
    Hortobagyi, GN
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 285 - 285
  • [42] An exploratory prospective clinical study on efficacy and safety of anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma
    Dong, P.
    Wei, W.
    Jiang, L.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    EUROPEAN UROLOGY, 2023, 83 : S753 - S753
  • [43] A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.
    Pili, Roberto
    Haas, Naomi B.
    Monk, Paul
    Logan, Theodore F.
    Narayan, Vivek
    Burney, Heather
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Clinical and immune characteristics of rapid dropout and long-term survival in a phase II safety and efficacy study of combination CRS-207/GVAX immunotherapy in pancreatic cancer.
    Le, Dung T.
    Whiting, Chan C.
    Lutz, Eric R.
    Nair, Nitya
    Engstrom, Amanda
    Lemmens, Ed
    Tagliaferri, Margit Cecile
    Murphy, Aimee L.
    Brockstedt, Dirk G.
    Jaffee, Elizabeth M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [45] Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): A phase II, prospective study
    Chen, J. Y.
    Zhang, H.
    Wang, B. Y.
    Wen, J. M.
    Xu, X. Y.
    Li, H. T.
    Fan, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1588 - S1588
  • [46] Stereotactic Radiotherapy (SRT) in Combination with Aumolertinib to Treat Intracranial Oligometastatic Non Small Cell Lung Cancer (NSCLC): An Update of a Phase II, Prospective Study
    Chen, J.
    Wang, B.
    Fan, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E94 - E94
  • [47] Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer
    Wu, Trudy C.
    Stube, Annalise
    Felix, Carol
    Oseguera, Denise
    Romero, Tahmineh
    Goldman, Jonathan
    Garon, Edward B.
    Lee, Jay M.
    Glaspy, John
    Lisberg, Aaron E.
    Rusthoven, Chad G.
    Camidge, D. Ross
    Siva, Shankar
    Solomon, Benjamin
    Lee, Alan
    Tenn, Stephen E.
    Shaverdian, Narek
    Steinberg, Michael L.
    Raldow, Ann C.
    Lee, Percy
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (01): : 118 - 122
  • [48] An open-label, single-arm, phase II study evaluating the efficacy and safety of niraparib combined with radiotherapy and teriprizumab in patients with recurrent small cell lung cancer
    Zeng, W.
    Xie, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S104 - S104
  • [49] Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naive-stage IV non-small cell lung cancer: A phase I study (IHC study).
    Xue, Jianxin
    Zhou, Xiaojuan
    Zhou, Laiyan
    Huang, Meijuan
    Gong, Youling
    Zou, Bingwen
    Zhu, Jiang
    Liu, Yongmei
    Peng, Feng
    Zhang, Yan
    Yu, Min
    Li, Yanying
    Na, Feifei
    Xiu, Weigang
    Zhang, Xuanwei
    Zhou, Lin
    Xu, Yong
    Wang, Jin
    Lu, You
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study
    Yuan, Dong-mei
    Lv, Yan-ling
    Yao, Yan-wen
    Miao, Xiao-hui
    Wang, Qian
    Xiao, Xin-wu
    Yin, Jie
    Shi, Yi
    Shi, Mei-qi
    Zhang, Xiu-wei
    Song, Yong
    THORACIC CANCER, 2012, 3 (04) : 341 - 347
12345